J Clin Res Pediatr Endocrinol. Ahead of Print: JCRPE-29981 | DOI: 10.4274/jcrpe.galenos.2024.2024-2-9

Treatment of Severe Hyperglycemia in Extremely Preterm Infants Using Continuous Subcutaneous Insulin Therapy

M. Boettger¹, T. Zhou², J. Knopp², J. Geoffrey Chase², A. Heep¹, M. von Vangerow¹, E. Cloppenburg¹, M. Lange^1
1Perinatal Neurobiology Research Group, School of Medicine and Health Sciences, Carl von Ossietzky University of Oldenburg, Oldenburg, Germany
²Department of Mechanical Engineering, University of Canterbury, Christchurch, New Zealand

INTRODUCTION: Hyperglycemia in preterm infants is usually treated with adjustment of glucose intake and, if persistent, with continuous insulin infusion. However, hypoglycemia is a well-known complication of iv insulin treatment. The aim of our study was to evaluate the feasibility of continuous subcutaneous insulin infusion (CSII) in extremely preterm infants.
METHODS: Clinical data from 15 extemely premature infants (< 28 weeks of gestation) undergoing CSII treatment for severe hyperglycemia at the NICU were included. Blood glucose levels during CSII as well as the nutritional intake and insulin intake were sampled. Data were analyzed and compared to a control group of very preterm infants receiving iv insulin therapy.
RESULTS: Normoglycemia rates were best in the iv insulin-cohort (50.3%; 15.6%). Hypoglycemia was very rare in both groups (0.4%; 0.0%). CSII therapy might require higher insulin doses compared to continuous iv therapy.
DISCUSSION AND CONCLUSION: Subcutaneous Insulin therapy in extremely preterm infants is feasible, regarding the prevention of hypoglycemia. However, dose control needs to be improved.
Conclusion: The results justify further model validation and clinical trial research to explore a model-based protocol and the use of CSII.

Keywords: Continuous subcutaneous insulin infusion, extremely preterm infants, hyperglycemia

---

CITE